Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals
- PMID: 37607330
- PMCID: PMC11291618
- DOI: 10.1093/ibd/izad175
Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals
Abstract
Background: Despite classical association between metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity, there is increasing evidence on the development of MASLD in lean individuals. The aim of the study was to assess the prevalence and risk factors of MASLD and significant liver fibrosis in lean participants with inflammatory bowel disease (IBD).
Methods: This was a cross-sectional, case-control study including 300 lean cases with IBD and 80 lean controls without IBD, matched by sex and age. All participants underwent a liver ultrasound, transient elastography, and laboratory tests.
Results: The lean IBD group showed a significantly higher prevalence of MASLD compared with lean non-IBD group (21.3% vs 10%; P = .022), but no differences were observed in the prevalence of significant liver fibrosis (4.7% vs 0.0%; P = 1.000). No differences were found between the prevalence of MASLD in IBD and non-IBD participants who were overweight/obese (66.8% vs 70.8%; P = .442). In addition, the prevalence of MASLD was significantly higher in the overweight/obese IBD group compared with the lean IBD group (P < .001). IBD was an independent risk factor for MASLD in lean participants (odds ratio [OR], 2.71; 95% confidence interval [CI], 1.05-7.01; P = .04), after adjusting for classic metabolic risk factors and prior history of systemic steroid use. Nevertheless, no association between IBD related factors and MASLD was identified in lean IBD participants. When the overweight/obese and lean IBD groups with MASLD were compared, the overweight/obese IBD group with MASLD showed higher levels of the homeostatic model assessment of insulin resistance (OR, 1.49; 95% CI, 1.11-1.98; P = .007) and history of smoking (OR, 4.66; 95% CI, 1.17-18.49; P = .029).
Conclusions: MASLD prevalence was higher in the lean IBD group compared with lean non-IBD group, independent of classic metabolic risk factors.
Keywords: Crohn’s disease; inflammatory bowel disease; lean MASLD; liver fibrosis; ulcerative colitis.
© 2023 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
Crohn´s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease.Eur J Intern Med. 2024 Feb;120:99-106. doi: 10.1016/j.ejim.2023.10.019. Epub 2023 Oct 21. Eur J Intern Med. 2024. PMID: 37872034
-
Incidence of metabolic dysfunction-associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study.J Gastroenterol Hepatol. 2024 Dec;39(12):2845-2852. doi: 10.1111/jgh.16755. Epub 2024 Sep 29. J Gastroenterol Hepatol. 2024. PMID: 39343427
-
Predictors of advanced liver fibrosis and the performance of fibrosis scores: lean compared to non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) patients.Minerva Gastroenterol (Torino). 2024 Sep;70(3):322-331. doi: 10.23736/S2724-5985.23.03518-0. Epub 2023 Oct 27. Minerva Gastroenterol (Torino). 2024. PMID: 37889111
-
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations.Clin Mol Hepatol. 2025 Jan;31(1):74-89. doi: 10.3350/cmh.2024.0631. Epub 2024 Oct 23. Clin Mol Hepatol. 2025. PMID: 39439408 Free PMC article. Review.
-
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. doi: 10.1016/S2468-1253(20)30077-7. Epub 2020 May 12. Lancet Gastroenterol Hepatol. 2020. PMID: 32413340
Cited by
-
Heavy arch: from inflammatory bowel diseases to metabolic disorders.Gut. 2024 Jul 11;73(8):1376-1387. doi: 10.1136/gutjnl-2024-331914. Gut. 2024. PMID: 38777571 Free PMC article. Review.
-
Dietary Determinants of Metabolic and Gut Microbial Health in Patients with Inflammatory Bowel Disease.Nutrients. 2024 Sep 24;16(19):3233. doi: 10.3390/nu16193233. Nutrients. 2024. PMID: 39408201 Free PMC article.
-
Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review.Cureus. 2024 Oct 14;16(10):e71451. doi: 10.7759/cureus.71451. eCollection 2024 Oct. Cureus. 2024. PMID: 39544615 Free PMC article. Review.
-
Cardiometabolic diseases in patients with inflammatory bowel disease: An evidence-based review.World J Gastroenterol. 2025 Jun 28;31(24):107661. doi: 10.3748/wjg.v31.i24.107661. World J Gastroenterol. 2025. PMID: 40599191 Free PMC article. Review.
-
Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Inflammatory Bowel Diseases: A Pilot Study.Life (Basel). 2024 Sep 25;14(10):1226. doi: 10.3390/life14101226. Life (Basel). 2024. PMID: 39459526 Free PMC article.
References
-
- Riazi K, Azhari H, Charette JH, et al.The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861. - PubMed
-
- Lazarus JV, Mark HE, Anstee QM, et al.; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60-78. - PubMed
-
- Younossi Z, Stepanova M, Ong JP, et al.; Global Nonalcoholic Steatohepatitis Council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748-755.e3. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources